Ávila NÁE, Chávez SGC, Astigueta PJCA

Language: Spanish
References: 12
Page: 130-135
PDF size: 706.85 Kb.

ABSTRACT

Introduction: Bilateral testicular cancer represents 5% of all testicular cancers, with an average age of presentation between the 15 and 35 years. 65% of the cases are presented as metachronous testicular cancer and of these 52% are seminomatous bilateral ones. Objective: To report the case of a patient with metachronous seminomatous bilateral testicular cancer. Case presentation: It was presented the case of a 27 year old male patient who coming from another institution was admitted at the Regional Institute of Neoplasic Diseases of Northern Peru, in order to receive treatment and postoperative actions. The patient had a history of having undergone a surgery of a tumor of germinal cells in the right testicle, and he was under chemotherapy. After that he remained free of the disease. Two years later, it was performed a Doppler ultrasound in the left testicle, and that reported a solid nodule in parenchyma, so he underwent testicular exploration and intraoperative cytology. The findings confirmed that it was a seminomatous germ cell tumor, so it was treated with surgery, chemotherapy and hormone replacement .At age 35 the patient is without evidence of the disease. Conclusions: Testicular cancer represents 1 to 1.5% of neoplasms in men; however, those patients with a history of unilateral testicular cancer are at higher risk of developing contralateral testicular cancer, even after receiving surgical treatment and chemotherapy. Some studies associate platinum chemotherapy with an increased risk of a second neoplasia.

REFERENCES

1. Arda E, Cakiroglu B, Cetin G, Yuksel I. Metachronous Testicular Cancer After Orchiectomy: A Rare Case. Cureus. 2017 [citado 09/11/2017]; 9 (11):e1833. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PM C5760111/

2. Soto Delgado M, Pedrero Márquez G, Arroyo Maestre JM, Beardo Villar P. Cáncer de testículo bilateral metacrónico. Aportación de un caso y revisión de la literatura. Rev Int Andrología. 2014 [citado 08/10/2017]; 12(2):76-9. Disponible en: https://medes.com/publication/89721

3. Sarıcı H, Telli O, Eroğlu M. Bilateral Testicular Germ Cell Tumors. Turk J Urol. 2013 [citado 04/01/2018]; 39(4):249. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/263281 19

4. Watson RA, Morgan RD, Joseph J, Sivakumar S, Verrill C, Tuthill M, et al. Bilateral Testicular Germ Cell Tumors: A Case-Series From a UKBased Tertiary Referral Center Over 19 Years. Clin Genitourin Cancer. 2018 [citado 09/11/2017]; 16(3):e513-e516. Disponible en: https://www.ncbi.nlm.nih.gov/.../query.fcgi?c md...Morgan%20RDau

5. Ortega-González ME, Hernández-Méndez EA, Cortes-Raygoza P, Calvo-Vázquez I, Veliz- Cabrera G, López-Maguey R. Tumores testiculares bilaterales: experiencia de 25 años en un hospital de tercer nivel de la ciudad de México. Rev Mex Urol. 2017 [citado 08/10/2017]; 77(5):353-60. Disponible en: www.medigraphic.com/cgibin/ new/resumen.cgi?IDARTICULO

6. Almazan-Treviño L, Rosas-Nava JE, Almanza- González MS. A metachronous testicular tumor 19 years later. Rev Mex Urol. 2014 [citado 06/12/2017]; 74(3):180-3. Disponible en: https://www.sciencedirect.com/science/article /pii/S200740851530034

7. Correa Ochoa JJ, Velásquez Ossa D, Lopera Toro AR, Martínez González CH, Yepes Pérez A. Guía colombiana de cáncer de testículo. Rev Urol Colomb. 2016 [citado 02/12/2017]; 25(3). Disponible en: www.redalyc.org/pdf/1491/149148397015.pdf

8. Kopp RP, Chevinsky M, Bernstein M, Bosl G, Motzer R, Bajorin D, et al. Bilateral Testicular Germ Cell Tumors in the Era of Multimodal Therapy. Urology. 2017 [citado 09/11/2017]; 103:154-60. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/278166 03

9. Quiñonez MAL. Uso de la quimioterapia en cáncer testicular de células germinales. Urol Colomb. 2014 [citado 09/11/2017]; 23(2):121-6. Disponible en: www.redalyc.org/pdf/1491/149131631007.pdf

10. Park DS, Prow DM, Amato RJ, Ro JY, Logothetis CJ. Clinical characteristics of metachronous bilateral testicular tumors in the chemotherapeutic era. Yonsei Med J. 1999 [citado 05/10/2017]; 40(2):137-43. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/103337 17

11. Van den Belt-Dusebout AW, de Wit R, Gietema JA, Horenblas S, Louwman MW, Ribot JG, et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5- year survivors of testicular cancer. J Clin Oncol. 2007 [citado 05/10/2017]; 25(28):4370-78. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/179062 02

12. Ondrus D, Hornák M, Mat'oska J. Bilateral testicular germ-cell tumors--a single centre longterm experience. Int Urol Nephrol. 2001 [citado 09/11/2017]; 33(3):521-4. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/1223028.